InnoDiss

Charite, IIIB and VISAMED received sup­port from BMBF under Grant 13GW0720 to devel­op a Stent­graft for min­i­mal-inva­sive Treat­ment of Acute Aor­tic Dis­sec­tion Type A. 

Car­dio­vas­cu­lar med­i­cine is under­go­ing a par­a­digm shift, with min­i­mal­ly inva­sive, catheter-based inter­ven­tion­al ther­a­pies like tran­scatheter aor­tic valve implan­ta­tion (TAVI) dis­rupt­ing tra­di­tion­al open-heart surgery. These tech­nolo­gies not only pro­vide new treat­ment options for high-risk patients but are increas­ing­ly replac­ing sur­gi­cal meth­ods for a broad­er pop­u­la­tion. This project aims to bring a sim­i­lar par­a­digm shift to the treat­ment of a rare, life-threat­en­ing car­dio­vas­cu­lar emer­gency: Acute Type A aor­tic dis­sec­tion (ATAAD).  ATAAD rep­re­sents an urgent unmet med­ical need, occurs when the inner wall of the ascend­ing aor­ta rup­tures, caus­ing the aor­tic wall lay­ers to split apart. This is a vas­cu­lar emer­gency with a very high case-fatal­i­ty rate. The cur­rent stan­dard of care is a high­ly inva­sive open-heart surgery, which is pro­hib­i­tive for a large pro­por­tion of patients due to exces­sive sur­gi­cal risks. While endovas­cu­lar repair has become the gold stan­dard for oth­er aor­tic dis­sec­tions, clin­i­cians are forced to rely on off-label use to treat ATAAD since there is no ded­i­cat­ed non-inva­sive device avail­able on the mar­ket, high­light­ing the crit­i­cal gap in avail­able treat­ment options. 

Pressemit­teilung: Charite

https://biermann-medizin.de/forschungsprojekt-innovativer-stent-als-alternative-zur-notoperation-bei-aortendissektion

https://www.facebook.com/herzzentrumcharite/posts/-wenn-die-hauptschlagader-einrei%C3%9Ft‑z%C3%A4hlt-jede-minuteeine-akute-typ-a-aortendisse/1197716218610887